1. Home
  2. PRG vs CGEM Comparison

PRG vs CGEM Comparison

Compare PRG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

N/A

Current Price

$39.49

Market Cap

1.7B

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$22.12

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
CGEM
Founded
2020
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PRG
CGEM
Price
$39.49
$22.12
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$50.00
$30.13
AVG Volume (30 Days)
431.0K
669.9K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
1.80
N/A
Revenue
$2,409,223,000.00
N/A
Revenue This Year
$23.77
N/A
Revenue Next Year
$7.91
$5.20
P/E Ratio
$21.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.80
$5.68
52 Week High
$47.73
$23.19

Technical Indicators

Market Signals
Indicator
PRG
CGEM
Relative Strength Index (RSI) 39.71 58.77
Support Level $38.13 $11.87
Resistance Level $41.14 $23.19
Average True Range (ATR) 1.15 1.01
MACD -0.15 -0.08
Stochastic Oscillator 26.57 55.78

Price Performance

Historical Comparison
PRG
CGEM

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: